Your Leading NF-ΚB Pathway Library Supplier

 

Suzhou Ureiko Medical Chemistry Technology Co.,Ltd, affiliated to Ureiko Group Co., Limited, is the world's leading supplier of scientific research chemicals and bioactive compounds, is always focus on R&D of signal transduction inhibitors and pharmaceutical intermediates. The product range covers a variety of inhibitors, agonists, and compound libraries. We follow closely the industry trend, and the latest research achievements in life science area.

 

 
 

Why choose us?

 

 

Our product
The product range covers a variety of inhibitors, agonists, and compound libraries, more than 10,000 specific inhibitors, agonists, and Libraries of over 100 active compounds

 

Product application
Ureiko is committed to providing industrial of small pharmaceutical molecules, fine chemicals, agricultural organic fertilizer, new building materials, electronic products, sporting goods, home daily necessities and so on, and become a comprehensive group company.

 

Production equipment
LCMS, HPLC, PreHPLC, NMR etc.

 

NIK SMI1 CAS No.:1660114-31-7

 

Overview Of NF-ΚB Signaling Pathway

Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kB) is a short name for Nuclear Factor kappa-light-chain-enhancer of activated B cells. It is a small family of inducible transcription factors that play a significant role in practically all mammalian cells, rather than a single protein. It regulates DNA transcription, cytokine synthesis, cell survival, and other key cell activities, and is particularly important in regulating the immunological response to infection.

 

NF-kB dimers are the most common type of NF-kB molecules. P50-P65 dimer (NF-kB1/RelA) is a common NF-kB structure. The development of a dimer is required for DNA binding because two NF-B monomers bind to DNA as a dimer.

 

 

Significance and Uses of NF-κB

NF-κB is important in regulating cellular responses because it belongs to the category of "rapid-acting" primary transcription factors. These transcription factors are present in cells in an inactive state and do not require new protein synthesis to be activated, allowing NF-κB to be a first and fast responder to harmful cellular stimuli. Receptor activator of nuclear factor kappa B, which is a type of TNFR, is a central activator of NF-κB. Many bacterial products and stimulation of a wide variety of cell-surface receptors lead to NF-κB activation and fairly rapid changes in gene expression.

NIK SMI1 CAS No.:1660114-31-7

 

Functions of Individual NF-κB Proteins in Immune Cells

 

 

The NF-κB/Rel family includes NF-κB1 (p50/p105), NF-κB2 (p52/p100), p65 (RelA), RelB, and c-Rel. Most members of this family (RelB being one exception) can homodimerize, as well as form heterodimers with each other. The most prevalent activated form of NF-κB is a heterodimer consisting of a p50 or p52 subunit and p65, which contains transactivation domains necessary for gene induction.

 

Studies in knockout mice have shown distinct functions for different members of the NF-κB/Rel family. Various NF-κB proteins play a pivotal role in defense of the host against certain pathogens. Furthermore, lack of RelA leads to embryonic lethality and liver degeneration in knockout mice, whereas mice lacking p50 or RelB are immunodeficient but otherwise develop normally to adulthood. B cells from p50 knockout mice show abnormal mitogen responses and antibody production. RelB plays a role in the development and differentiation of dendritic cells, and a mutation disrupting relB impairs antigen presentation. Other NF-κB proteins, including C-Rel and p52, are also essential for normal immune function. Of interest, unlike either of the corresponding single knockout mice, p50/p52 double knockout mice exhibit impaired development of osteoclasts and B cells.

 

The expression of NF-κB proteins can provide site- and event-specificity in response to a particular stimulus. For instance, IL-1–induced collagenase expression in synoviocytes is primarily activated by p50 homodimers that bind to a critical NF-κB–like binding site. Both p50 and p65 play a role in constitutive IL-6 production in rheumatoid arthritis (RA) synovial fibroblasts, whereas p65 activation by thrombin regulates ICAM-1 expression in endothelial cells. p50 and p65 heterodimers are intimately involved in activation of inflammatory genes by IL-1 or TNF-α in human monocytes, and these effects are blocked by the anti-inflammatory cytokine IL-10. Additional specificity is provided by the expression patterns of other regulatory molecules, including surface receptors to proinflammatory cytokines as well as the hierarchy of IKK and IκB isotypes in each cell lineage. These differences, along with multiple variations in NF-κB–like binding sites that interact with certain NF-κB hetero- and homodimers, permit cells to respond to the external environment at the appropriate time with the correct genes.

 

Signaling Pathway Key

 

 

productcate-554-151

 

Composition and activation of NF-κB
NIK SMI1 CAS No.:1660114-31-7
NIK SMI1 CAS No.:1660114-31-7
NIK SMI1 CAS No.:1660114-31-7
NIK SMI1 CAS No.:1660114-31-7

NF-κB is formed through the homo- or hetero-dimerization of members of the Rel family of DNA binding proteins. In mammals these include RelA (p65), c-rel, RelB, p105 (the precursor of p50), and p100 (the precursor of p52). Each member of this family contains a Rel homology domain (RHD), which itself consists of a DNA binding region, a dimerization region and a nuclear localization signal.

 

NF-κB activity is regulated by family of proteins known as IκBs which include IκBα, IκBβ, IκBγ, IκBε and Bcl-3. When in their inactivated state, NF-κB complexes are localized in the cytoplasm, in complex with IκB kinase-α (IKKα), IκB kinase-β (IKKβ) and IKKγ/NEMO, a non-enzymatic protein that may function as a scaffold. The IKK complex can be activated by various cytokines, inflammatory molecules and stress signals.

 

In the canonical pathway, activated IKKb phosphorylates IkB which is subsequently ubiquitinated and marked for degradation by proteases. This releases NF-κB from the IkB-containing complex and unmasks the nuclear localization signal (NLS). An NF-κB complex composed of RelA/c-Rel/p50 will then translocate to the nucleus where it can activate the transcription of its target genes. In the non-canonical pathway, p100 is degraded to p52, allowing a RelB/p52 complex to translocate from the cytoplasm to the nucleus.

 

Depending on the composition of NF-κB in the nucleus, different genes will be actively transcribed. This variation and specificity in gene targets is further determined by the post translational modification of different subunits, such as the phosphorylation of p65.

 

A vast range of genes are targeted by NF-κB, including that of its own inhibitor, IkB. In this case, newly produced IkB will bind to the NF-κB complex and increase its localization in the cytoplasm, thus representing a negative auto regulatory feedback loop for NF-κB activity.

 

Certificate

 

20230731101220465c11bb4540425a97c12fe3f359512e.jpg (410×582)

 

FAQ

 

Q: What is the NF-κB pathway?

A: The canonical NF-κB pathway responds to diverse stimuli, including ligands of various cytokine receptors, pattern-recognition receptors (PRRs), TNF receptor (TNFR) superfamily members, as well as T-cell receptor (TCR) and B-cell receptor.

Q: Is NF KB good or bad?

A: NF-κB can also prevent programmed necrosis by inducing genes encoding antioxidant proteins. Since tumor cells often use NF-κB to achieve resistance to anticancer drugs and radiations, inhibition of NF-κB activation appears as a promising option to improve the efficacy of conventional anti-cancer therapies.

Q: What is the role of NF-κB in epithelial biology?

A: NF-κB inhibition in keratinocytes triggered severe tumor necrosis factor-dependent skin inflammation and epidermal hyperplasia, while inhibition of IKK/NF-κB signaling in intestinal epithelial cells disturbed the intestinal barrier and triggered severe chronic colon inflammation.

Q: What is the mapk NF-κB signaling pathway?

A: Mitogen-activated protein kinase (MAPK) and NF-κB pathways are common inflammatory signaling pathways. Activation of MAPKs and NF-κB pathways, caused proinflammatory cytokines such as interleukin-6 (IL-6), IL-8, and tumor necrosis factor-α (TNF-α) to be released, which could lead to the inflammatory response.

Q: What happens when NFKB is activated?

A: Upon activation, canonical NF-κB induces the production of proinflammatory cytokines such as TNF-α and IL-1β in the innate immune system, resulting in inflammatory response. On the other hand, these proinflammatory cytokines activate canonical NF-κB.

Q: What does the activation of NF-κB require?

A: Activation of NF-kappa B Requires Proteolysis of the Inhibitor I Kappa B-alpha: Signal-Induced Phosphorylation of I Kappa B-alpha Alone Does Not Release Active NF-kappa B.

Q: What happens when NF-kB is inhibited?

A: Inhibition of NF-κB activation can reduce cyclin D1 activity and subsequent phosphorylation of the retinoblastoma protein to result in delayed cell cycle progression. This impaired cell cycle progression can be rescued by ectopic expression of cyclin D1.

Q: Does NF-kB cause apoptosis?

A: Activation of the transcription factor NF-κB has been linked to apoptosis, with the factor playing either an anti-apoptotic or a pro-apoptotic role, depending on the type of cell in which it is expressed.

As one of the most professional nf-κb pathway library enterprises in China, we're featured by small molecules chemicals and inhibitors. Please rest assured to buy custom made nf-κb pathway library from our factory. For OEM service, contact us now.

Shopping Bags